Idiosyncratic drug-induced liver injury (DILI) is a type of hepatic injury caused by an
uncommon drug adverse reaction that can develop to conditions spanning from …

Background Function and expression Arylamine N-acetyltransferases (NATs) are
xenobioticmetabolizing enzymes for which three distinct enzymatic activities have been …

BACKGROUND AND OBJECTIVE: Although a series of studies have evaluated the potential
association between N-acetyltransferase 2 (NAT2) polymorphisms and the risk of anti …

Background Three first-line antituberculosis drugs, isoniazid, rifampicin and pyrazinamide,
may induce liver injury, especially isoniazid. This antituberculosis drug-induced liver injury …

Although severe idiosyncratic drug–induced liver injury (DILI) is a rare event, it has a large
impact on the fate of affected patients and the incriminated drug. Hepatic metabolism of …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The pharmacokinetic properties of
isoniazid are well characterized, having been studied in seminal work beginning in the early …

There is considerable evidence that susceptibility to idiosyncratic drug-induced liver injury
(DILI) is genetically determined. Though genetic associations with DILI have been reported …

Considerable progress has been made in identifying genetic risk factors for idiosyncratic
adverse drug reactions in the past 30 years. These reactions can affect various tissues and …

Background More than 1 million tuberculosis (TB) patients are receiving directly observed
treatment strategy (DOTS) therapy in China every year. As to the profile of adverse drug …

Background Implication of pharmacogenetic variations and efavirenz pharmacokinetics in
concomitant efavirenz based antiviral therapy and anti-tubercular drug induced liver injury …